Balyasny Asset Management
SMMT icon

Balyasny Asset Management’s Summit Therapeutics SMMT Stock Holding History

Balyasny Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,600
Closed -$268K – 3429
2025
Q2 		$268K Buy
+12,600
New +$287K ﹤0.01% 2509

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Balyasny Asset Management's SMMT Position: Q2 2026 in Review

Balyasny Asset Management increased its Summit Therapeutics (SMMT) stake by 247% in Q2 2026, buying an estimated $24M and bringing the position to 1,904,254 shares worth $27.7M. The position accounts for 0.03% of the portfolio, ranked #576.

Balyasny Asset Management first reported a position in SMMT in Q1 2023 and has held it in 10 quarters since. The position peaked at $32.9M in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Balyasny Asset Management held 1,904,254 shares of Summit Therapeutics worth $27.7M as of Q2 2026.
  • Balyasny Asset Management bought 1,355,919 Summit Therapeutics shares in Q2 2026, an estimated $24M.
  • Summit Therapeutics made up 0.03% of Balyasny Asset Management's portfolio in Q2 2026, its #576 holding.
  • Balyasny Asset Management first reported a position in Summit Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Balyasny Asset Management's Summit Therapeutics position peaked at $32.9M in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.